NCT05413044 2025-12-08
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
Bristol-Myers Squibb
Completed
Clinical Trials
24 trialsNCT05421442 2025-12-08
DANBIO
Bristol-Myers Squibb
Completed
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT01086059 2025-01-28
OTIS Humira Pregnancy Registry
University of California, San Diego
Completed
NCT04721821 2024-04-12
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Pfizer
Completed
NCT05447182 2024-02-05
PPM:RANT
Brigham and Women's Hospital
Completed
NCT04952896 2022-11-02
Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease
Peking University Third Hospital
Completed
NCT04798287 2022-06-22
STAR-RA-Cancer
Brigham and Women's Hospital
Completed
NCT03670667 2022-05-18
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
Bristol-Myers Squibb
Completed
NCT03663829 2022-03-09
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
Bristol-Myers Squibb
Completed
NCT01764321 2020-12-22
NexT
UCB Pharma
Completed
NCT03941184 2020-11-23
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Mayo Clinic
Completed
NCT03348046 2020-03-04
PASSRRA
Hikma Pharmaceuticals LLC
Completed
NCT01060098 2020-01-18
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Imperial College London
Completed
NCT02778789 2019-09-26
Re-Bone
University of Erlangen-Nürnberg Medical School
Completed
NCT02679001 2018-07-26
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
Hoffmann-La Roche
Completed
NCT01362062 2017-08-02
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Hoffmann-La Roche
Completed
NCT01613027 2016-10-24
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
Hoffmann-La Roche
Completed
NCT02927509 2016-10-07
Evaluation of Tumour Necrosis Factor Alpha (TNFα) Blockers in Early Rheumatoid Arthritis in France
Centre Hospitalier Universitaire de NÄ«mes
Completed
NCT01641952 2016-08-17
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
Hoffmann-La Roche
Completed
NCT01309282 2016-08-12
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
Hoffmann-La Roche
Completed
NCT01069419 2015-10-29
FasT
UCB Pharma
Completed
NCT01294722 2013-03-19
A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea
Janssen Korea, Ltd., Korea
Completed
NCT01078571 2011-10-28
DALI
Abbott
Completed